Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE)

OBJECTIVE: Evaluate apremilast efficacy across various psoriatic arthritis (PsA) manifestations beginning at week 2 in biological-naïve patients with PsA. METHODS: Patients were randomised (1:1) to apremilast 30 mg twice daily or placebo. At week 16, patients whose swollen and tender joint counts ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Nash, Peter, Ohson, Kamal, Walsh, Jessica, Delev, Nikolay, Nguyen, Dianne, Teng, Lichen, Gómez-Reino, Juan J, Aelion, Jacob A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909747/
https://www.ncbi.nlm.nih.gov/pubmed/29343507
http://dx.doi.org/10.1136/annrheumdis-2017-211568

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909747/
https://www.ncbi.nlm.nih.gov/pubmed/29343507
http://dx.doi.org/10.1136/annrheumdis-2017-211568

Ejemplares similares